July 22, 2015
Genetic Signatures gains FDA Listing for EasyScreen™ Sample Processing Kit
- First regulatory step towards full product suite commercialisation in US
- Enables US sales of the kit to broad customer base
Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced it has received a United States Food and Drug Administration (FDA) listing for it’s clinical sample concentrator, the EasyScreen™ Sample Processing Kit (SP001). The FDA listing means that the company can legally sell it’s EasyScreen™ Sample Processing Kit in the US, a first step in the further release of other EasyScreen™ products planned for US markets.
July 20, 2015
CFO Presentation at 2015 Bioshares Biotech Summit
Genetic Signatures CFO Rob Birrell recently presented at the 11th Bioshares Biotech Summit in Queenstown held on Friday 17- Saturday 18 July, 2015. The presentation featured in a session titled New IPOs, with a focus on biotech companies that have listed in the last 12 months, their respective IPO experiences and the value propositions of the newly listed companies. The presentation slides can be downloaded here
About the Bioshares Biotech Summit: The Summit is organised by Bioshares, Australia’s leading independent biotech investment publication. Attendees include biotech executives, fund managers and, retail investors.
May 25, 2015
25th May 2015 – GSS Non-Deal Roadshow Presentation
April 27, 2015
Quarterly Cash Flow Report – GSS Appendix 4C 31 March 2015
April 10, 2015
Completion of first customer site installation of new EasyScreen™ Respiratory Virus Detection Kit
- « Previous
- 1
- …
- 23
- 24
- 25
